Valis Bioscience focuses on improving the measurement and treatment of psychiatric and neurological disorders. The company specializes in psychedelic trials and rare and orphan disorders, developing tools for clinical trials and digital therapeutics.

Valis Bioscience

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL  Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences, Inc.

Numinus Wellness Inc. provides solutions to develop and deliver psychedelic-assisted psychotherapy and transform the mental health landscape. The company operates in two divisions, Salvation Botanicals and Numinus Health. The Salvation Botanicals division offers laboratory services, such as cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics; and full suite testing and custom testing of cannabis. The Numinus Health division provides supportive therapies and technologies to heal, connect, and grow with a focus on treating mental health and substance abuse; and services for psychotherapy, counselling, neurofeedback, physiotherapy, and other therapies. This division also offers training, facilities, and other operational resources to practitioners. The company is headquartered in Vancouver, Canada.

Numinus Wellness Inc.

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Srinivas Rao

Florian Brand

Christian Angermayer

Lars Christian Wilde

Atai Life Sciences N.V.

Valis Bioscience | 635 followers on LinkedIn. TECHNOLOGY + RESEARCH | Valis is a patient-centric company. Founded on the ideals of advancing medicine, medical research, and the technologies surrounding how we diagnose, treat, and understand neurological disorders, every service we provide and technology we develop comes from our fundamental goal of helping people.

The founders of Valis Bioscience came from the medical research world, and have dozens of years of experience in clinical trials for a broad spectrum of indications.

Business and Technology Transformation Strategist | ICMI Top 25 CX and Contact Center Thought Leader

Dmitri Novomeiski

Technology Lead | Product Owner | AWS | DevOps

Sheraz Hussain

Chief Scientific Officer at Valis Bioscience

Christian Yavorsky

QA Team Lead | Sr. Automation Test Engineer | Compliance and Validation Engineer | PMO Expert| | Agile Scrum || ERP, EMR, EHR E2E Tester

Adnan Jamil Choudhry

We’re #hiring a new Quality Assurance Engineer in Lahore, Punjab. Apply today or share this post with your network.

We’re #hiring a new L3 Support Engineer in Lahore, Punjab. Apply today or share this post with your network.

Metric
Company Name	Valis Bioscience	Neurocrine Biosciences, Inc.	Numinus Wellness Inc.	Atai Life Sciences N.V.
Symbol		NBIX	NUMI	ATAI
MSH ID	COM:VALISBIOSCIENCE	COM:NEUROCRINE	COM:NUMINUS	LIFE:ATAI
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare
Industry	Clinical Research	Drug Manufacturers - Specialty & Generic	Medical - Care Facilities	Biotechnology
Country	US	US	CA	DE
Stage
Employee Count		1.45K	200	83
Website	valisbioscience.com	neurocrine.com	numinus.com	atai.life
LinkedIn	valisbioscience		numinus
Founders

Metric
Market Cap	14.81B	9.07M	220.98M
Enterprise Value
Monthly Web Traffic	11.48K
Web Traffic Growth	0.19
Valuation
Raised Capital

Metric
Revenue	1.89B	16.40M	314.00K
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.85B	5.92M	-5K
EBITDA	250.90M	-17.43M	-125.15M
Operating Income	250.90M	-19.44M	-125.47M
Net Income	249.70M	-21.40M	-40.22M
EPS	2.56	-0.08	-0.25
Diluted EPS	2.47	-0.08	-0.25
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.98	0.35	0.32
Operating Profit Margin	0.26	-0.93	-291.29
EBITDA Margin	0.13	-1.06	-398.57
Net Profit Margin	0.19	-1.17	-122.03
Return on Equity	0.17	-1.49	-0.14
Return on Assets	0.11	-1.40	-0.13
Return on Capital Employed	0.19	-1.54	-0.45

VALI

COM:VALISBIOSCIENCE

Valis Bioscience

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	72.61	-1.07	-4.03
P/B Ratio	6.93	3.00	1.02
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.54	1.04	1.95K
EV Multiple	35.09	-0.27	-1.78

Metric
Days Sales Outstanding	85.49	35.49	1.66K
Days Payables Outstanding		59.40
Days Inventory Outstanding	372.00	4.17	0.00
Operating Cycle	452.63	39.66	11.66K
Cash Conversion Cycle	452.63	-13.85	7.57K
Asset Turnover	0.64	1.53	0.00

Metric
Operating Cash Flow	389.90M	-16.10M	-84.12M
Free Cash Flow	361.60M	-16.37M	-84.71M
Cash Flow to Debt	2.52	-2.80	-4.26
Operating Cash Flow/Sales	0.33	-0.68	-206.82
Free Cash Flow Yield	0.03	-0.62	-0.32

Metric
Cash & Equivalents	251.10M	6.07M	45.03M
Accounts Receivable	-89.30M	-937.23K	-2.01M
Inventory	38.30M		1
Goodwill
Debt to Capitalization	0.19	0.40	0.10
Debt to Assets	0.09	0.35	0.05
Current Ratio	2.39	2.10	11.04
Quick Ratio	4.08	2.09	10.69

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.11	0.09	113.22
R&D to Revenue	0.31	0.03	209.35
SG&A to Revenue		1.23	179.30